TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well...

Related Keywords

Alexandria ,Al Iskandariyah ,Egypt ,David Licata ,Lyell Immunopharma ,John Glaspy ,Martina Mcdermott ,Amit Sinha ,Neil Obrien ,Mark Attanasio ,Leonard Presta ,Dennis Slamon ,Sarah Larson ,Brian Lawliss ,Tom Boone ,Ben Hoffstrom ,Mark Alles ,Lynn Seely ,Head Of Life Sciences ,Sachs Co ,Crandon Law ,Bristol Myers Squibb ,Latham Watkins ,Celgene Corporation ,Crescent Capital Group ,Goldman Sachs ,University Of California At Los Angeles ,Slamon Research Lab ,Keck School Of Medicine ,Perceptive Xontogeny Venture Fund ,David Geffen School Of Medicine ,Division Of Hematology Oncology ,Los Angeles ,Executive Chairman Mark Alles ,Seriesb Financing ,Goldman Sachs Asset Management ,Chief Investment Officer ,Deep Track Capital ,Vertex Ventures ,Moore Strategic Ventures ,Cowen Healthcare Investments ,Alexandria Venture Investments ,Life Sciences Investing ,Geffen School ,Goldman Sachs Asset ,Associate Professor ,Adjunct Assistant Professor ,Assistant Professor ,Keck School ,Managing Partner ,Torl Biotherapeutics Llc ,